This appraisal has formally started. However, the company that markets methynaltrexone bromide subcutaneous formulation has informed us that they will not provide an evidence submission for this appraisal for commercial reasons. NICE will therefore suspend this appraisal with immediate effect and provide further updates when they are available.
 
Status Suspended
Process STA pre-2018

Project Team

Project lead Stephanie Yates

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics – York

Consultees

Companies sponsors Swedish Orphan Biovitrum (methylnaltrexone bromide)
Others Department of Health
  NHS England
  NHS Bath and North East Somerset CCG
  NHS Wiltshire CCG
  Welsh Government
Patient carer groups Action on Pain
  Black Health Agency
  Bladder and Bowel Foundation
  Cancer Black Care
  Cancer Equality
  HAWC
  Helen Rollason Cancer Charity
  IBS Network
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie Cancer Care
  Muslim Council of Britain
  Pain Concern
  Pain Relief Foundation
  Pain UK
  Promocon
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  Association of Coloproctology of Great Britain and Ireland
  Association for Continence Advice
  Association for Palliative Medicine
  British Geriatrics Society
  British Pain Society
  British Psychosocial Oncology Society
  British Society of Gastroenterology
  Cancer Research UK
  Primary Care Society for Gastroenterology
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Health Forum
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Actavis UK (glycerol suppositories, bisacodyl)
  Boehringer Ingelheim (bisacodyl, docusate, macrogol, sodium picosulphate)
  Cardinal Health Martindale Products (glycerol suppositories)
  Laboratorios Casen Fleet (sodium dihydrogen phosphate dehydrate, disodium hydrogen phosphate dodecahydrate enema)
  Chanelle Medical (bisacodyl, macrogol)
  Chatfield Pharmaceuticals (bisacodyl)
  Chemidex Pharma (phosphate enema, arachis oil enema)
  Hermal (ispaghula husk, glycerol suppositories)
  Medreich (bisacodyl)
  Meda Pharmaceuticals (macrogol)
  Napp Pharmaceuticals Limited (naloxone-oxycodone)
  Norgine Pharmaceuticals (sterculia/ frangula, macrogol, docusate sodium enema)
  Orbis Consumer Products (glycerol suppositories)
  Pinewood Healthcare (sodium citrate enema)
  ProStrakan/Kyowa Kirin (naloxegol)
  Thornton & Ross (macrogol, magnesium hydroxide, glycerol suppositories)
  UCB Pharma (sodium citrate enema, docusate)
General commentators Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
Relevant research groups Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group
  CORE (Digestive Disorders Foundation)
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
06 June 2016 Suspended, This appraisal has formally started. However, the company that markets methynaltrexone bromide subcutaneous formulation has informed us that they will not provide an evidence submission for this appraisal for commercial reasons. NICE will therefore suspend this appraisal with immediate effect and provide further updates when they are available.
19 April 2016 Invitation to participate
09 October 2015 - 09 October 2015 Draft scope documents
16 September 2015 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance